CXCL9 and hepatocellular carcinoma: For example, Sitagliptin treatment improves anti-tumour responses via enhanced CCL11-mediated eosinophil migration in hepatocellular carcinoma mouse models [45], and promotes CXCL9- and CXCL10-mediated dendritic cell trafficking to melanoma tumours [46].